HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results on May 14, 2026, underscoring significant progress in the commercial launch of its FDA-cleared cardiac monitoring platform. The company announced initial commercial partnerships in key U.S. markets, advancement of its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds.
For the first quarter ended March 31, 2026, HeartBeam reported a net loss of $4.7 million, an improvement from the $5.5 million net loss in the prior-year period. Research and development expenses declined year over year as the company shifted focus toward commercialization of its platform technology. The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed to enable cable-free, portable cardiac monitoring.
HeartBeam's platform allows for the collection of ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG. This technology is intended for use outside medical facilities, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. The company holds over 20 issued patents related to its technology enablement.
The full press release is available at https://ibn.fm/guMCF. For more information about HeartBeam and its cleared indications for use, visit https://www.heartbeam.com/indications.
The latest news and updates relating to HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT.
This announcement is important as it marks the transition of HeartBeam from a development-stage company to a commercial-stage entity, with initial partnerships and a strengthened balance sheet supporting its mission to transform cardiac care through innovative 3D ECG technology.